Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian Biotech Viralytics Breaks Out With Doubling Deal

This article was originally published in PharmAsia News

Executive Summary

With one deal, Australia’s Viralytics doubles its market capitalization to $48 million from $24 million, which can bring its lead melanoma product through trials to commercialization.

You may also be interested in...



Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace

Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.

Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.

Prima Shifts Focus To LAG-3 After Immutep Deal

The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel